Publications 2009
Original Papers
- Eichenauer D, Bredenfeld H, Haverkamp H, Müller H, Fuchs M, Borchmann P, Müller-Hermelink H-K, Eich HT, Müller R-P, Diehl V, Engert A. Hodgkin lymphoma in adolescents treated with adult protocols: a report from the German Hodgkin Study Group (GHSG). J Clin Oncol 2009; 27 (36): 6079-85.
- Engert A, Diehl V, Franklin J, Lohri A, Dörken B, Ludwig WD, Koch P, Hänel M, Pfreundschuh M, Wilhelm M, Trümper L, Aulitzky WE, Bentz M, Rummel M, Sezer O, Müller-Hermelink HK, Hasenclever D, Löffler M. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol. 2009; 27(27):4548-54. [Follow-Up HD9]
- Markova J, Kobe C, Skopalova M, Klaskova K, Dedeckova K, Plütschow A, Eich HT, Dietlein M, Engert A, Kozak T. FDG-PET for assessment of early treatment response after four cycles of chemotherapy in patients with advanced-stage Hodgkin's lymphoma has a high negative predictive value. Ann Oncol 2009; 20 (7): 1270-4.
- Reiners KS, Gossmann A, von Strandmann EP, Böll B, Engert A, Borchmann P. Effects of the anti-VEGF monoclonal antibody bevacizumab in a preclinical model and in patients with refractory and multiple relapsed Hodgkin lymphoma. J Immunother. 2009 Jun;32(5):508-12.
Reviews
- Eichenauer DA, Engert A. Is there a role for BEACOPP (bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, prednisone) in relapsed Hodgkin lymphoma? Leuk Lymphoma. 2009 Nov;50(11):1733-4.
- Klimm B, Engert A. Combined modality treatment of Hodgkin's lymphoma.Cancer J. 2009; 15(2):143-9.
- Kobe C, Dietlein M, Fuchs M. Interpretation and validation of interim positron emission tomography in Hodgkin lymphoma. Leuk Lymphoma 2009; 50(11): 1761-4.